Artivion, Inc. (NYSE:AORT) Given Average Recommendation of “Moderate Buy” by Brokerages

Artivion, Inc. (NYSE:AORT) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $47.8333.

A number of brokerages recently issued reports on AORT. LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a research note on Friday, April 10th. Stifel Nicolaus set a $55.00 price target on shares of Artivion in a research note on Thursday, March 5th. Needham & Company LLC lowered their target price on shares of Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Finally, Citizens Jmp lowered their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th.

Artivion Stock Up 0.3%

Shares of NYSE:AORT opened at $22.74 on Friday. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $33.64 and a 200 day simple moving average of $39.72. The firm has a market cap of $1.10 billion, a PE ratio of 94.77 and a beta of 1.41. Artivion has a 12-month low of $19.16 and a 12-month high of $48.25.

Insider Activity

In other Artivion news, SVP Jean F. Holloway sold 8,962 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total transaction of $340,556.00. Following the completion of the sale, the senior vice president owned 185,095 shares in the company, valued at $7,033,610. The trade was a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Amy Horton sold 901 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $34,039.78. Following the sale, the chief accounting officer owned 139,088 shares of the company’s stock, valued at approximately $5,254,744.64. The trade was a 0.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 133,043 shares of company stock valued at $4,977,158 over the last quarter. 6.30% of the stock is owned by company insiders.

Institutional Trading of Artivion

Institutional investors have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd grew its position in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Artivion during the third quarter worth about $27,000. Rockefeller Capital Management L.P. grew its position in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after acquiring an additional 399 shares during the last quarter. Larson Financial Group LLC grew its position in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after acquiring an additional 563 shares during the last quarter. Finally, USA Financial Formulas grew its position in shares of Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after acquiring an additional 703 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.